Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Panbela Therapeutics, Inc. | ex_176447.htm |
| EX-31.2 - EXHIBIT 31.2 - Panbela Therapeutics, Inc. | ex_176446.htm |
| EX-31.1 - EXHIBIT 31.1 - Panbela Therapeutics, Inc. | ex_176445.htm |
| EX-24.1 - EXHIBIT 24.1 - Panbela Therapeutics, Inc. | ex_177167.htm |
| EX-23.1 - EXHIBIT 23.1 - Panbela Therapeutics, Inc. | ex_177166.htm |
| EX-10.25 - EXHIBIT 10.25 - Panbela Therapeutics, Inc. | ex_177933.htm |
| EX-10.22 - EXHIBIT 10.22 - Panbela Therapeutics, Inc. | ex_177932.htm |
| EX-10.10 - EXHIBIT 10.10 - Panbela Therapeutics, Inc. | ex_177931.htm |
| EX-4.1 - EXHIBIT 4.1 - Panbela Therapeutics, Inc. | ex_177165.htm |
| 10-K - FORM 10-K - Panbela Therapeutics, Inc. | snbp20191231_10k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Susan Horvath, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
the Annual Report on Form 10-K of Sun BioPharma, Inc. for the year ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Sun BioPharma, Inc. |
Dated: March 24, 2019
|
/s/ Susan Horvath |
|
|
Susan Horvath |
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer and Principal |
|
|
Accounting Officer) |